2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-109091B
    Lanraplenib succinate 1800047-00-0 98.09%
    Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
    Lanraplenib succinate
  • HY-135382A
    PROTAC IRAK4 degrader-3 2374122-43-5 98.24%
    PROTAC IRAK4 degrader-3 is a PROTAC-induced IRAK4 degrader based on von Hippel-Lindau.
    PROTAC IRAK4 degrader-3
  • HY-136093B
    Lixumistat 1422365-93-2 99.33%
    Lixumistat (IM156 free base) is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis.
    Lixumistat
  • HY-147404A
    Tilpisertib fosmecarbil TFA 2567459-65-6 98.05%
    Tilpisertib fosmecarbil TFA (GS 5290 TFA) is a potent serine/threonine kinase inhibitor. Tilpisertib fosmecarbil TFA has anti-inflammatory activity.
    Tilpisertib fosmecarbil TFA
  • HY-153220A
    (R)-Zelebrudomide 3024312-52-2 98.93%
    (R)-Zelebrudomide ((R)-NX-2127) ((R)-Compound 28) is an isomer of the BTK PROTAC degrader Zelebrudomide (HY-153220). (Pink: BTK ligand 10 (HY-168302); Black: (S)-4-(1-(Pyrrolidin-3-ylmethyl)piperidin-4-yl)aniline (HY-168303); Blue: Thalidomide 5-fluoride (HY-W087383).
    (R)-Zelebrudomide
  • HY-N0733S3
    Glucosamine-6-13C hydrochloride 98.0%
    Glucosamine-6-13C (hydrochloride) is the 13C labeled Glucosamine hydrochloride. Glucosamine hydrochloride (D-Glucosamine hydrochloride) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as
    Glucosamine-6-13C hydrochloride
  • HY-W014423S2
    L-Histidine-13C6 hydrochloride hydrate 201740-88-7 98.00%
    L-Histidine-13C6 (hydrochloride hydrate) is the 13C-labeled L-Histidine hydrochloride hydrate (HY-W014423). L-Histidine hydrochloride hydrate is an endogenous metabolite. L-Histidine hydrochloride hydrate scavenges hydroxyl radicals and singlet oxygen, regulate the absorption of zinc, copper and iron, exhibits anti-inflammatory and antioxidant activities. L-Histidine hydrochloride hydrate is blood brain barrier penetrable.
    L-Histidine-13C6 hydrochloride hydrate
  • HY-16718
    Dagrocorat 1044535-52-5 99.90%
    Dagrocorat (PF-00251802) is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor. Dagrocorat is also a time-dependent reversible inhibitor of CYP3A (IC50=1.3 μM in human liver microsomes) and CYP2D6 (Ki=0.57 μM in human liver microsomes). Dagrocorat can be used for the research of rheumatoid arthritis.
    Dagrocorat
  • HY-16722
    Fosdagrocorat 1044535-58-1 98.70%
    Fosdagrocorat (PF-04171327) is a dissociated glucocorticoid receptor agonist.
    Fosdagrocorat
  • HY-17494
    Timolol 26839-75-8
    Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect.
    Timolol
  • HY-44809
    Izilendustat 1303512-02-8
    Izilendustat is a potent prolyl hydroxylase inhibitor. Izilendustat competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia.
    Izilendustat
  • HY-P2221
    Glepaglutide 914009-86-2 99.53%
    Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease.
    Glepaglutide
  • HY-101793
    BMS-935177 1231889-53-4 98.35%
    BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 3 nM.
    BMS-935177
  • HY-106835
    Flobufen 112344-52-2 98%
    Flobufen (VUFB 16066) is a non-steroidal anti-inflammatory agent and cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitor agent. Flobufen inhibits alloantigen-driven cellular immune responses and stimulates phagocytosis of peritoneal cells. Flobufen can improve immunopathological disorders and has an inhibitory effect on rheumatoid arthritis.
    Flobufen
  • HY-107781
    PAT-505 1782070-22-7 99.47%
    PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.
    PAT-505
  • HY-109097
    Otaplimastat 1176758-04-5 98.11%
    Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury.
    Otaplimastat
  • HY-112267
    Olacaftor 1897384-89-2 99.60%
    Olacaftor (VX-440) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator extracted from patent US9782408.
    Olacaftor
  • HY-112427
    Sirt2-IN-1 1862238-00-3 98.71%
    Sirt2-IN-1 (Compound 9) is a sirtuin 2 (Sirt2) inhibitor with an IC50 of 163 nM.
    Sirt2-IN-1
  • HY-114404
    SJFα 2254609-27-1 99.61%
    SJFα is a selective p38α PROTAC degrader with a DC50 of 7.16   nM and Dmax of 97.4%. SJFα is far less effective at degrading p38δ (DC50 = 299 nM). SJFαcan be used for the research of cancer, such as breast cancer.
    SJFα
  • HY-118250
    GSK2245035 1207629-49-9 99.79%
    GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma.
    GSK2245035
Cat. No. Product Name / Synonyms Application Reactivity